Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27090259 | 0.95 | ESR1 (0.75) | ESR1ESR2RAB9AMAPTNPC1 | |
| SCHEMBL8034090 | 0.88 | ESR1 (0.81) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL4058336 | 0.88 | ESR1 (0.56) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL9197043 | 0.88 | ESR1 (0.65) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL9196837 | 0.88 | ESR1 (0.66) | ESR1ESR2RAB9AMAPTNPC1 | |
| SCHEMBL3013427 | 0.87 | MEN1 (0.62) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL27090226 | 0.87 | ESR1 (0.73) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL27090228 | 0.86 | ESR1 (0.96) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL2158317 | 0.84 | ESR1 (1.00) | ESR1ESR2RAB9AMEN1MAPT | |
| SCHEMBL3938979 | 0.83 | ESR1 (1.00) | ESR1ESR2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052103-A1 | POLYMER AND TRIAZINE COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-02-15 | — | — | US | disclosed |
| EP-2350032-B1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2016-05-25 | — | — | EP | disclosed |
| EP-2350032-B1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354400-B2 | Benzoxazole compounds and methods of use | EISAI R&D CO., LTD. (JP) | 2013-01-15 | — | — | US | disclosed |
| EP-2350032-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| WO-2010036905-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036905-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036908-A1 | USE OF BENZOXAZOLE COMPOUNDS IN THE TREATMENT OF MALARIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183967-A1 | BENZOXAZOLE COMPOUNDS AND METHODS OF USE | CYP4X1, CYP3A5, CYP3A7 | ESR1 2407/4885ESR2 2935/4885RAB9A 4299/4885 |
| US-20240052103-A1 | POLYMER AND TRIAZINE COMPOUND | TERT, TERB1, MCM5 | ESR1 3620/4885ESR2 2848/4885RAB9A 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.